Tetraphase Pharmaceuticals (TTPH) PT Raised to $13 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Tetraphase Announces Positive Top-Line Results from Phase 3 IGNITE4 Clinical Trial in Complicated Intra-Abdominal Infections
July 25, 2017 4:01 PM EDTÂ Â IV Eravacycline Achieves Primary Endpoint in Second of Two Pivotal Trials in cIAIÂ
  Company Proceeding with Regulatory Submissions in Europe in 3Q 2017 and U.S. in 1Q 2018  Â
  Ongoing Phase 3 IGNITE3 Clinical Trial in cUTI Expected to Complete Enrollment Early 4Q 2017 Â
  Conference Call Scheduled for Today at 5:00 p.m. ET Â
WATERTOWN, Mass., July 25, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:... More
